Back

A de novo systematic literature review to identify the clinical effectiveness and safety of different treatments for patients with non-obstructive hypertrophic cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Phenotyping in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Michael Hurst

Cardiff (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Sudden cardiac death HCM risk scores in apical hypertrophic cardiomyopathy: an unmet need in clinical practice
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Left ventricular global deformation index, evaluating a novel echocardiographic marker for prediction of heart failure in asian patients with hypertrophic cardiomyopathy
Doctor T. Li (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Genetic influences on clinical outcomes in hypertrophic cardiomyopathy: comparative insights into MYH7, MYBPC3 and TPM1 gene mutations
Doctor M. Vilela (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Real-world clinical and economic outcomes of nonobstructive hypertrophic cardiomyopathy: a german claims data analysis
Associate Professor F. Sedaghat-Hamedani (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
The relationship between the presence of genetic mutations and left atrial function in hypertrophic cardiomyopathy
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotyping in hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Clinical burden of obstructive and non-obstructive hypertrophic cardiomyopathy: insights from a nationwide study in France
thumbnail
Congress Presentation
Comparisons in cardiovascular outcomes and mortality in patients diagnosed with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Real-world insights into mavacamten use for obstructive hypertrophic cardiomyopathy: symptomatic improvement before gradient reduction?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources